Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
EB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial Reported preclinical data demonstrating that EB-003 consistently…
1 source
·2h ago